[1] 陈宜瑜. 繁荣基础研究 服务创新型国家建设[EB/OL].[2014-10-30]. http://www.cas.cn/xw/kjsm/gndt/200906/t20090608_647808.shtml.
[2] Kon A A. The clinical and translational science award (CTSA) consortium and the translational research model[J]. The American Journal of Bioethics, 2008, 8(3): 58-60.
[3] Alving B, Dai K, Chan S H H. Translational medicine-what, why and how: an international perspective[M]. Karger Medical and Scientific Publishers, 2013:110-119.
[4] Narin F, Noma E. Is technology becoming science?[J]. Scientometrics, 1985, 7(3-6): 369-381.
[5] Glanzel W, Meyer R M. Patents cited in the scientific literature: An exploratory study of reverse citation relations[J]. Scientometrics, 2003, 58(2):415-428.
[6] 赵志耘, 雷孝平.我国生物科技领域技术创新与基础研究关联分析——从专利引文分析的角度[J].情报学报,2012,31(12): 1283-1289.
[7] 李睿,肖恒,容军凤,等.试论"科学关联"计量指标的不足及改进——双向引用信息融合视角[J].情报理论与实践,2013,36(8):6-10.
[8] Rinia E J, van Leeuwen T N, Bruins E E W. Measuring knowledge transfer between fields of science[J]. Scientometrics,2002,54(3): 347-362.
[9] 赵星,谭旻,余小萍, 等.我国文科领域知识扩散之引文网络探析[J].中国图书馆学报,2012, 38(5): 59-67.
[10] Liu Yuxian, Rousseau R. Interestingness and the essence of citation[J]. Journal of Documentation, 2013, 69(4): 580-589.
[11] 杜建,唐小利,张燕舞,等.引文网络加速转化医学T1-T2-T3阶段的转化进程[J].中华临床营养杂志,2013,21(2):98-102.
[12] Narin F, Pinski G, Gee H H. Structure of the biomedical literature[J]. Journal of the American Society for Information Science, 1976, 27(1): 25-45.
[13] McMillan G S, Narin F, Deeds D L. An analysis of the critical role of public science in innovation: The case of biotechnology[J]. Research Policy, 2000, 29(1): 1-8.
[14] Grant J, Cottrell R, Cluzeau F, et al. Evaluating "payback" on biomedical research from papers cited in clinical guidelines: Applied bibliometric study[J]. British Medical Journal, 2000, 320(7242): 1107-1111.
[15] Boyack K W, Klavans R. Multiple dimensions of journal specificity: Why journals can't be assigned to disciplines[C]//The 13th Conference of the International Society for Scientometrics and Informetrics. Durban, South Africa, 2011: 123-133.
[16] Lewison G, Paraje G. The classification of biomedical journals by research level[J]. Scientometrics, 2004, 60(2): 145-157.
[17] Cambrosio A, Keating P, Mercier S, et al. Mapping the emergence and development of translational cancer research[J]. European Journal of Cancer, 2006, 42(18): 3140-3148.
[18] Boyack K W, Richard K, Patek M, et al. An indicator of translational capacity of biomedical researchers[C]//The 18th International Conference on Science and Technology Indicators. Berlin: 2013:52-61.
[19] Harris J K, Luke D A, Zuckerman R B, et al. Forty years of secondhand smoke research: The gap between discovery and delivery[J]. American Journal of Preventive Medicine, 2009,36(6):538-548.
[20] Kryl D, Allen L, Dolby K, et al. Tracking the impact of research on policy and practice: Investigating the feasibility of using citations in clinical guidelines for research evaluation[J]. BMJ Open, 2012,2(2):e000897.
[21] Weber G M. Identifying translational science within the triangle of biomedicine[OL].[2014-08-10].http://www.translational-medicine.com/content/11/1/126.
[22] Fajardo-Ortiz D, Duran L, Moreno L, et al. Liposomes vs metallic nanostructures: Differences in the process of knowledge translation in cancer[J]. International Journal of Nanomedicine, 2014, 26(9):2627- 2634.
[23] Campbell E G, Powers J B, Blumenthal D, et al. Inside the triple helix:Technology transfer and commercialization in the life sciences[J]. Health Affairs, 2004, 23(1):64-76.
[24] Fajardo-Ortiz D, Duran L, Moreno L, et al. Mapping knowledge translation and innovation processes in cancer drug development: The case of liposomal doxorubicin[OL].[2014-08-10].http://www.translational-medicine.com/content/11/1/126.
[25] McMillan G, Narin F, Deeds D. An anaiysis of the critical role of public science in innovation: The case of biotechnoiogy[J]. Research Policy, 2000,29(1): 1-8.
[26] 桂捷. 基础研究与专利发明之间的关系测度研究[D]. 北京: 北京理工大学, 2007.
[27] 文晓芬. 基于专利引文的我国基础研究与技术创新的关联分析[D]. 北京: 中国科学技术信息研究所, 2011.
[28] Morris Z S, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research[J]. Journal of the Royal Society of Medicine, 2011,104(12):510-520.
[29] Contopoulos-Ioannidis D G, Alexiou G A, Gouvias T C, et al. Life cycle of translational research for medical interventions[J]. Science, 2008, 321(5894):1298-1299.
[30] Chen E S, Sarkar I N. MeSHing molecular sequences and clinical trials:A feasibility study[J]. Journal of Biomedical Informatics, 2010, 43(3):442-450.
[31] Huang M C, Fang S C, Chang S C. Tracking R&D behavior: Bibliometric analysis of drug patents in the orange book[J]. Scientometrics, 2011, 88(3):805-818.
[32] Rubio D M, Sufian M, Trochim W M. Strategies for a national evaluation of the clinical and translational science Awards[J]. Clinical and Translational Science, 2012, 5(2):138-139.
[33] Trochim W M, Rubio D M, Thomas V G, et al. Evaluation guidelines for the clinical and translational science award[J]. Clinical and Translational Science, 2013,6(4):303-309.
[34] Sarli C C. Beyond citation analysis:A model for assessment of research impact[J]. Journal of The Medical Library Association, 2010,98(1): 17-23.
[35] Sarli C C, Holmes K L. Update to "Beyond citation analysis: A model for assessment of research impact"[J]. Journal of The Medical Library Association, 2012,100(2):82.
[36] Kellogg Foundation. Logic model development guide[EB/OL]. [2014-08-10]. http://www.wkkf.org/resource-directory/resource/2006/02/wk-kellogg-foundation-logic-model-development-guide.
[37] Dembe A E, Lynch M S, Gugiu P C, et al. The translational research impact scale: Development, construct validity, and reliability testing[J]. Evaluation & the Health Professions, 2014, 37(1):50-70.
[38] Scott C S, Nagasawa P R, Abernethy N F, et al. Expanding assessments of translational research programs: Supplementing metrics with value judgments[J]. Evaluation & the Health Professions, 2014,37(1):83-97.
[39] Rajan A, Sullivan R, Bakker S, et al. Critical appraisal of translational research models for suitability in performance assessment of cancer centers[J]. Oncologist, 2012,17(12):e48-57.
[40] Rajan A, Caldas C, van Luenen H, et al. Assessing excellence in translational cancer research: A consensus based framework[OL].[2014-08-10].http://www.translational-medicine.com/content/11/1/126.
[41] Grether M, Eickelberg O, Mall M A, et al. New metrics for translational research[J]. The Lancet Respiratory Medicine, 2014,2(8):e13-e14.
[42] 董尔丹, 胡海, 洪微. 浅析转化医学与医学实践[J]. 科学通报, 2013, 58(1): 53-62.
[43] 姜永茂,朱永赞,张悦,等.香山科学会议第S13次学术讨论会在京召开转化医学成为会议焦点[J].中华医学信息导报,2011,26(4):1-3.
[44] Volberding P. The impact of HIV research on health outcome and healthcare policy[J]. Annals of Oncology, 2011, 22(Suppl 7): vii50-vii53.
[45] Walker R L, Sykes L, Hemmelgarn B R, et al. Authors' opinions on publication in relation to annual performance assessment[OL].[2014-08-10].http://www.translational-medicine.com/content/11/1/126.
[46] Patel V M, Ashrafian H, Ahmed K, et al. How has healthcare research performance been assessed?: A systematic review[J]. Journal of the Royal Society of Medicine, 2011, 104(6):251-61.
[47] 董尔丹,胡海,张俊. 学术评价应更科学[J]. 科学通报, 2014, 59(1): 96-106.
[48] Kuruvilla S, Mays N, Pleasant A, et al. Describing the impact of health research: A research impact framework[OL].[2014-08-10].http://www.translational-medicine.com/content/11/1/126.
[49] 旧金山科研评价宣言小组. 关于科研评价的旧金山宣言——让科研评价更加科学[J].李宏,王建芳,译.图书情报工作动态, 2013(5):3-4.
[50] McNutt M. The measure of research merit[J]. Science, 2014, 346(6214): 1155. |